表纸
市场调查报告书

男性性腺功能低下症 : 开发平台分析

Male Hypogonadism - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 232815
出版日期 内容资讯 英文 103 Pages
订单完成后即时交付
价格
Back to Top
男性性腺功能低下症 : 开发平台分析 Male Hypogonadism - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 103 Pages
简介

男性性腺功能低下症的主要症状、有倦怠感、身体的发热、不孕、肌肉量的减少、骨质疏松症。男性性腺功能低下症容易发病的环境、有HIV/AIDS、柯林菲特氏症、卡尔曼氏症候群、睾丸的负伤、睡眠呼吸中止症等。

本报告提供男性性腺功能低下症治疗药的开发情形的相关调查、开发中产品的概要、临床实验的各阶段的产品概要、主要企业简介、药物简介、开发中产品的最新趋势等。

简介

  • 调查范围

男性性腺功能低下症概要

治疗药的开发

  • 开发中产品的概要
  • 开发中产品比较分析

男性性腺功能低下症:企业开发中的治疗药

男性性腺功能低下症:开发中产品概况

  • 后期阶段的产品
  • 临床阶段的产品
  • 初期阶段的产品
  • 开发阶段不明的产品

男性性腺功能低下症:企业开发中的产品

男性性腺功能低下症治疗药的开发企业

  • Antares Pharma, Inc.
  • BIOCAD
  • Clarus Therapeutics, Inc.
  • Diurnal Limited
  • EndoCeutics, Inc.
  • Ferring International Center S.A.
  • Forendo Pharma Limited
  • Lipocine Inc.
  • M et P Pharma AG
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Monosol Rx, LLC
  • Pantarhei Bioscience BV
  • Repros Therapeutics Inc.

男性性腺功能低下症:治疗药的评估

  • 单剂产品
  • 各标靶
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • BGS-649
  • corifollitropin alfa
  • enclomiphene
  • fispemifene
  • follitropin alfa
  • Kisspeptin-10
  • Libidua
  • LPCN-1111
  • MSS-722
  • T-2
  • TAK-448
  • TBS-1
  • Testavan
  • testosterone
  • testosterone
  • testosterone
  • testosterone
  • testosterone enanthate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate

男性性腺功能低下症:最近的开发平台趋势

男性性腺功能低下症:暂停中的计划

男性性腺功能低下症:开发中止的产品

男性性腺功能低下症:产品开发的里程碑

  • 主要消息和新闻稿

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11083IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H1 2019, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 4, 7, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Male Hypogonadism - Overview
  • Male Hypogonadism - Therapeutics Development
  • Male Hypogonadism - Therapeutics Assessment
  • Male Hypogonadism - Companies Involved in Therapeutics Development
  • Male Hypogonadism - Drug Profiles
  • Male Hypogonadism - Dormant Projects
  • Male Hypogonadism - Discontinued Products
  • Male Hypogonadism - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Male Hypogonadism, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Male Hypogonadism - Pipeline by Allergan Plc, H1 2019
  • Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H1 2019
  • Male Hypogonadism - Pipeline by Diurnal Group Plc, H1 2019
  • Male Hypogonadism - Pipeline by EndoCeutics Inc, H1 2019
  • Male Hypogonadism - Pipeline by Ferring International Center SA, H1 2019
  • Male Hypogonadism - Pipeline by Lipocine Inc, H1 2019
  • Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2019
  • Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H1 2019
  • Male Hypogonadism - Pipeline by Merck & Co Inc, H1 2019
  • Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H1 2019
  • Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H1 2019
  • Male Hypogonadism - Pipeline by Viramal Ltd, H1 2019
  • Male Hypogonadism - Dormant Projects, H1 2019
  • Male Hypogonadism - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Male Hypogonadism, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top